[go: up one dir, main page]

WO2016199002A1 - Crème médicale préparée en utilisant du furoate de mométasone et en incorporant un biopolymère et procédé pour la préparer - Google Patents

Crème médicale préparée en utilisant du furoate de mométasone et en incorporant un biopolymère et procédé pour la préparer Download PDF

Info

Publication number
WO2016199002A1
WO2016199002A1 PCT/IB2016/053261 IB2016053261W WO2016199002A1 WO 2016199002 A1 WO2016199002 A1 WO 2016199002A1 IB 2016053261 W IB2016053261 W IB 2016053261W WO 2016199002 A1 WO2016199002 A1 WO 2016199002A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
cream
amount
chitosan
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2016/053261
Other languages
English (en)
Inventor
Subramaniam Vanangamudi Sulur
Murali MR. S
Madhavan MR. SRINIVASAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US15/368,559 priority Critical patent/US20170119788A1/en
Publication of WO2016199002A1 publication Critical patent/WO2016199002A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Definitions

  • Dermatitis is an inflammation of the skin. Dermatitis actually refers to a number of skin conditions that inflame the skin. Dermatitis is characterized by skin that may be red, swollen, blistered, scabbed, scaly, oozing, or itchy. Some types of dermatitis are caused by allergies, while the majority does not have any known causes.
  • Dermatitis There are many types of dermatitis that require clinical care by a physician or other healthcare professional. The following are some of the examples of Dermatitis: Atopic Dermatitis (Eczema), Contact Dermatitis, Dermatitis Herpetiformis, Generalized Exfoliative Dermatitis, Seborrheic Dermatitis.
  • Wounds are heterogeneous and the wound healing process is of a multifactorial nature, influenced by many factors and compounds, introduced externally.
  • wound pharmacology is the study of agents and their actions in wound environment.
  • agents drugs, biologies and special biologies such as those produced by biotechnology.
  • Conventional drugs can be categorized by route of administration (Topical, Systemic or Both).
  • the kinetics are relatively easy to study and can serve as a guide for development of more complex agents.
  • biologies are naturally occurring synthetic or modified proteins and carbohydrates.
  • Dermatological conditions are often caused by allergy accompanied by inflammation, tissue damage, irritation and itching.
  • Topical and systemic inflammatory treatment compositions typically employ corticosteroids in a base component.
  • the active ingredients typically comprise Corticosteroids such as Betamethasone dipropionate, Beclomethasone dipropionate, Hydrocortisone, Clobetasol propionate, Clobetasone butyrate, Halobetasol propionate, Mometasone furoate, Halcinonide, Fluocinonide, Triamcinolone acetonide, Fluticasone propionate, Amcinonide, Hydrocortisone acetate, Diflorasone diacetate, Prednicarbate and like.
  • Chitosan is a biopolymer with skin regeneration and rejuvenation properties due to its unique physical nature. Chitosan acts as a biocatalyst in accelerating the wound healing. Due to its positive charge it couples with negatively charged blood cells and aids in clotting of blood. It also helps in controlling the microbial mobility because of its charge and prevents spread of infections. As a micro-film forming bio material, Chitosan helps in reducing the width of the wound, controls the oxygen permeability at the site, and absorbs wound discharge, which is very much essential for faster wound healing. It also reduces the itching by providing a soothing effect.
  • Wound healing or wound repair, is the body's natural process of regenerating dermal and epidermal tissue. When an individual is wounded, a set of complex biochemical events takes place in a closely orchestrated cascade to repair the damage.
  • Wound healing is a complicated process that recruits at least 4 distinct cell types. Though the process is continuous, it is commonly referred to as occurring in "phases.”
  • the main phases of wound healing include coagulation, which begins immediately after injury; inflammation, which initiates shortly thereafter; a migratory and proliferate process, which begins within days and includes the major processes of healing; and a remodeling process, which may last for up to a year and is responsible for scar tissue formation and development of new skin.
  • Wound healing is affected by several factors. These include local factors (growth factors, edema and ischemia, low oxygen tension, and infection), regional factors (arterial insufficiency, venous insufficiency and neuropathy), systemic factors (inadequate perfusion and metabolic disease) and other miscellaneous factors, such as nutritional state, preexisting illnesses, exposure to radiation therapy and smoking.
  • local factors growth factors, edema and ischemia, low oxygen tension, and infection
  • regional factors arterial insufficiency, venous insufficiency and neuropathy
  • systemic factors inadequate perfusion and metabolic disease
  • other miscellaneous factors such as nutritional state, preexisting illnesses, exposure to radiation therapy and smoking.
  • chronic wounds may be managed by preventing or medically treating infections through debridement and occlusive dressings. For wounds that are unresponsive to such interventions, the use of skin replacements is becoming a viable option. Wound healing is essential to continued life. Its components overlap and are commonly seen as "phases”.
  • Coagulation performs its function of hemostasis, initiating healing and leaving behind messengers that bring on an inflammatory process. Inflammation protects the wound from infection and leaves behind its own set of messengers, important signals that bring on the migration and proliferation of macrophages, lymphocytes, fibroblasts, keratinocytes and endothelial cells. A phase follows in which fibroblasts become dominant and a collagenous matrix is deposited. Finally, there is a remodeling process that rarely restores full, normal structure. Each of these components plays a specific and irreplaceable role in the continuum of healing. A delay in, or absence of any one can result in a prolongation or even a prohibition of healing.
  • Figure 1 shows the film formed when using the formulation of the present invention.
  • the present invention is directed to a composition for treating skin inflammation (Dermatitis), skin regeneration & rejuvenation and wound healing containing a) A Chitosan component which is an unbranched binary polysaccharides consisting of the two units N-acetyl-D-glucosamine and D-glucosamine used for the treatment of skin regeneration & rejuvenation and wound healing. b) Corticosteroids like Mometasone Furoate used in treating skin inflammations. c) A cream base containing any of the ingredients selected from a group comprising primary and secondary emulsifiers, waxy materials, co- solvents, acids, preservatives, buffering agents, anti-oxidants, chelating agents and humectants. d) Water
  • the active ingredients a Chitosan component, a corticosteroid are incorporated in cream base for use in treating skin inflammation due to allergy & itching, & wounds on human skin involving contacting human skin with the above identified composition.
  • the active compounds which may be employed in the present invention are topical corticosteroids like Mometasone Furoate and a bio polymer for treating skin inflammation and wounds.
  • suitable biopolymer include, but are not limited to Chitosan and the like.
  • Suitable topical Corticosteroids include, but are not limited to, Mometasone Furoate, and like.
  • actives require a base component to be used in the pharmaceutical composition that uses the actives, since the actives cannot, by themselves, be deposited directly on to human skin due to their harshness.
  • the base component usually contains primary and secondary emulsifiers, waxy materials, co-solvents, acids, and preservatives, buffering agents, chelating agents, humectants and the like.
  • Chitosan is an un-branched binary polysaccharide consisting of the two units N-
  • Chitosan is Poly- ⁇ - (1, 4)-2-Amino-2-deoxy-D-glucose. Chitosan is produced by partial deacetylation (Not less than 70 %) of Chitin, which is extracted from the shells of shrimp and crab. Chitosan finds its application in various areas including Pharmaceutical, Cosmetics and Food industry. It is official in Ph. Eur. and proposed to be official in USP as an excipient. It is used as a film forming, mucoadhesive and viscosity-increasing agent. It is also used as a binder and disintegrating agent in tablet formulations.
  • Chitosan generally absorbs moisture from the atmosphere / environment and the amount absorbed depends upon the initial moisture content, temperature and relative humidity of the environment.
  • Chitosan due to its unique physical property accelerates wound healing and wound repair. It is positively charged and soluble in acidic to neutral solution. Chitosan is bioadhesive and readily binds to negatively charged surfaces such as mucosal membranes. Chitosan enhances the transport of polar drugs across epithelial surfaces. The properties of Chitosan allow it to rapidly clot blood, and have recently gained approval in the USA for its use in bandages and other hemostatic agents. Chitosan is hypoallergenic, and has natural anti-bacterial properties, further supporting its use. A therapeutic application for chitin was first recognized by fishermen in ancient China who revered it for its natural wound healing properties. More recently a number of scientific studies have been conducted to investigate how chitin and its derivative chitosan may modulate wound healing.
  • Chitosan helps in reducing the width of the wound, controls the oxygen permeability at the site, absorbs wound discharge and gets degraded by tissue enzymes which are very much required for healing at a faster rate. It also reduces the itching by providing a soothing effect. It also acts like a moisturizer.
  • Wound repair is a complex process involving an integrated response by many different cell types controlled by a variety of growth factors.
  • fibroblasts start to enter the wound where they synthesize and later remodel new extracellular matrix material of which collagen is the main component.
  • the dermal response is only one aspect of cutaneous wound repair however, the outermost and vital barrier layer, the epidermis which is composed of several layers of keratinocytes must also be restored.
  • basal layer keratinocytes migrate from the wound edge and from injured epidermal appendages (hair follicles and sweat glands) into the defect, moving over the newly formed dermal scaffolding. They proliferate, stratify and differentiate to produce a neo-epidermis to cover the wound and restore the skin's barrier function.
  • Topical corticosteroids are a powerful tool for treating skin diseases.
  • Corticosteroids include drugs like Mometasone Furoate , Betamethasone dipropionate, Beclomethasone dipropionate, Hydrocortisone, Clobetasol propionate, Clobetasone butyrate, Halobetasol propionate, Halcinonide, Fluocinonide, Triamcinolone acetonide, Fluticasone propionate, Amcinonide, Hydrocortisone acetate, Diflorasone diacetate, Prednicarbate, etc. Understanding the correct use of these agents will result in the successful management of a variety of skin problems.
  • Topical corticosteroids have anti-inflammatory, antipruritic and vasoconstrictive properties.
  • Corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor Arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. Topical corticosteroids are classified by their potency, ranging from weak to extremely potent. They include weak potent steroids, moderate potent steroids, potent steroids, very potent steroids and extremely potent steroids.
  • the high potency steroids include Mometasone Furoate, Betamethasone Dipropionate, Betamethasone Valerate, Diflorasone Diacetate, Clobetasol Propionate, Halobetasol Propionate, Desoximetasone, Diflorasone Diacetate, Fluocinonide, Triamcinolone Acetonide, etc.
  • Low potency topical steroids include Desonide, Fluocinolone acetate, and Hydrocortisone, etc. Topical corticosteroid is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.
  • Mometasone Furoate is a synthetic corticosteroid with anti- inflammatory activity Chemically, Mometasone Furoate is 9a, 21-dichloro-l ip, 17-dihydroxy-16a- methylpregna-1, 4-diene-3, 20-dione 17-(2 -Furoate), with the empirical formula C27H30CI2O6, and a molecular weight of 521.4 g/mol.
  • Mometasone Furoate is a white to off-white powder practically insoluble in water, slightly soluble in octanol, and moderately soluble in ethyl alcohol. Mometasone Furoate is a medium potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid- responsive dermatoses. Pharmacology
  • Mometasone Furoate is a medium-potency synthetic corticosteroid with antiinflammatory, antipruritic, and vasoconstrictive properties. Mometasone Furoate depresses formation, release, and activity of endogenous mediators of inflammation, including prostaglandins, kinins, histamine, liposomal enzymes, and complements system; modifies body's immune response.
  • Mometasone Furoate have been shown to have a wide range of inhibitory effects on multiple cell types (e.g. mast cells, eosinophils, neutrophils, macrophages and lymphocytes) and mediators (e.g. histamine, eicosanoids, leukotrienes, and cytokines) involved in inflammation and in the asthmatic response. These antiinflammatory actions of corticosteroids may contribute to their efficacy in asthma and in skin lesions.
  • mediators e.g. histamine, eicosanoids, leukotrienes, and cytokines
  • Unbound Mometasone Furoate cross cell membranes and bind with high affinity to specific cytoplasmic receptors. Inflammation is decreased by diminishing the release of leukocytic acid hydrolases, prevention of macrophage accumulation at inflamed sites, interference with leukocyte adhesion to the capillary wall, reduction of capillary membrane permeability, reduction of complement components, inhibition of histamine and kinin release, and interference with the formation of scar tissue.
  • the antiinflammatory actions of Mometasone Furoate are thought to involve phospholipase A 2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.
  • Mometasone Furoate has been shown in vitro to exhibit a binding affinity for the human glucocorticoid receptor which is approximately 12 times that of dexamethasone, 7 times that of triamcinolone acetonide, 5 times that of budesonide, and 1.5 times that of fluticasone. Pharmacokinetics
  • Mean C maX ranged from 94 to 114 pcg/mL and the time to C maX ranged from about 1 to 2.5 h.
  • Mometasone Furoate is primarily and extensively metabolized in the liver by the CYP3 A4 isozyme to multiple metabolites. Elimination
  • Terminal t 1 ⁇ 2 of Mometasone Furoate is about 5 h. Excretion up to 7 days is primarily in the feces (74%) and, to a lesser amount, in the urine (8%).
  • Mometasone Furoate is a medium potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid- responsive dermatoses.
  • Creams are semisolid emulsions, which are mixtures of oil and water in which APIs (Active Pharmaceutical Ingredients) are incorporated. They are divided into two types: oil-in-water (O/W) creams which compose of small droplets of oil dispersed in a continuous water phase, and water-in-oil (W/O) creams which compose of small droplets of water dispersed in a continuous oily phase. Oil-in-water creams are user-friendly and hence cosmetically acceptable as they are less greasy and more easily washed with water.
  • An ointment is a viscous semisolid preparation containing APIs, which are used topically on a variety of body surfaces.
  • the vehicle of an ointment is known as ointment base.
  • the choice of a base depends upon the clinical indication of the ointment, and the different types of ointment bases normally used are:
  • Hydrocarbon bases e.g. hard paraffin, soft paraffin
  • the acidic scale of pH is from 1 to 7, and the base scale of pH is from 7 to 14.
  • Human skins pH value is somewhere between 4.5 and 6. Newborn baby's skin pH is closer to neutral (pH 7), but it quickly turns acidic. Nature has designed this probably to protect young children's skin, since acidity kills bacteria. As people become older, the skin becomes more and more neutral, and won't kill as many bacteria as before. This is why the skin gets weak and starts having problems.
  • the pH value goes beyond 6 when a person actually has a skin problem or skin disease. This shows that it is necessary to choose topicals that have a pH value close to that of skin of a young adult.
  • cream formulations are available as creams. Active compounds in cream formulations are available in ionized state, whereas in case of ointments these are present in non -ionized state.
  • the cream formulations are the first choice of the formulators in design and development of topical dosage forms, as the cream formulations are cosmetically elegant, and also as the active compound is available in ionized state, and the drug can penetrate the skin layer fast which makes the formulation totally patient friendly.
  • the pH of the Chitosan Cream with Mometasone Furoate, of the present invention is from about 3 to 6.
  • ointments that are commercially available are greasy and cosmetically non elegant.
  • the active compound in an ointment is in non-ionized form, the penetration of skin is slow.
  • the active drug penetrates the skin for the optimum bio-dermal efficacy.
  • the particle size of the active drug plays an important role here. It is necessary that the active drug is available in colloidal or molecular dispersed state for the product being highly efficacious form. This is to be achieved in the safe pH compatible environment of skin (3.0 to 6.0). To achieve all these, it is essential to choose proper vehicles or co-solvents for the dissolution or dispersion of the drug.
  • the product of the invention is highly efficacious due to the pronounced anti-inflammatory and wound healing activity of the active ingredients, which are available in ultramicro-size/colloidal form, which enhances skin penetration.
  • Mometasone Furoate provides much wanted rapid relief of the pruritus. Therapy with only Mometasone Furoate is recommended for severe eczematic eruptions to provide instant relief to patients from itching and burning. Also the monotherapy with Mometasone Furoate will help in avoiding the allergenic response to antifungals and antibacterials. The inclusion of Chitosan in the formulation takes care of many attributes, which are considered to be very much essential in preventing the degradation of Mometasone Furoate.
  • the OH group at Cn position may interact with NH 2 group of Chitosan by hydrogen bonding. (N-H+ O-H) thus stabilizing the Mometasone Furoate.
  • Mometasone Furoate As Chitosan is a film forming, biocompatible, non-allergenic biopolymer, it protects the skin by acting as a barrier. In a therapy, Mometasone Furoate takes care of the inflammation. But the issues like skin protection, mobility of pathogens from one site to another, etc are not addressed so far. This present invention will fill this gap by an innovative technology of incorporating Chitosan and tapping the required benefits of skin protection (by way of film forming property), immobilization of pathogenic microbes (due to its cationic electrostatic property) and wound healing.
  • Chitosan is regarded as a non-toxic and non-irritant material. It is biocompatible with both healthy and infected skin and has been shown to be biodegradable as it is derived from shrimps and crabs.
  • GAGs GlycosAminoGlycans
  • GAGs like Heparin, Heparin sulfate, Hyaluronic acid and Keratin sulfate are all derivatives of 2-amino-2-deoxy-D-glucose) and present in all parts of human body.
  • GAGs are essential building blocks of macromolecular frame work of connective and other tissues. Fetal wounds are known to heal without scars and this has been attributed to fetal skins being rich in hyaluronic acid (Hyaluronan).
  • Chitosan/Polyglucosamine is structurally similar to hyaluronan and is expected to assist scarless wound healing. Heparin enhances mitogen by induction and stabilization of fibroblast growth stimulating factor (FGF). Polyglucosamine may promote tissue growth and wound healing by forming complexes with heparin and acting to prolong the half-life of the growth factors. Chitosan is hypoallergenic, and has natural anti-bacterial properties, further supporting its use.
  • FGF fibroblast growth stimulating factor
  • Chitosan helps in reducing the width of the wound, controls the oxygen permeability at the site, absorbs wound discharge and gets degraded by tissue enzymes which are very much required for healing at a faster rate. It also reduces the itching by providing a soothing effect. It also acts like a moisturizer.
  • novel cream of the present invention are most stable/efficacious at ambient conditions and does not need special temperature control during transportation/storage - hence will go a long way in achieving the objectives.
  • the unique innovative formulation of the present invention takes care of the skin conditions by treating them along with controlling the superficial bleeding at the site. It is well understood that if the superficial bleeding is left untreated, it will lead to secondary microbial infections.
  • the present invention advantageously provides a solution to this unmet need.
  • the stability of the product is confirmed by the stability studies performed for 36 months as per ICH guidelines and a comparison of stress studies done for the present invention and samples of commercially available comparable products.
  • Embodiment 1 A medicinal cream for topical treatment of skin inflammations, and for related wound healing, wherein said cream comprises Mometasone Furoate, and a biopolymer provided in a cream base, said cream base comprising at least one of each of a primary and a secondary emulsifier, a waxy material, a co-solvent, a preservative, an acid, penetration enhancer, a chelating agent, a buffering agent and water, preferably purified water.
  • Embodiment no. 2 A medicinal cream as disclosed in the embodiment no. 1, wherein said cream further comprising any of a group comprising an antioxidant, a humectant, or any combination thereof.
  • Embodiment no. 3 A medicinal cream as disclosed in the embodiment no. 1 wherein
  • said Mometasone Furoate is added in an amount between about 0.001% (w/w) and about 5% (w/w), preferably between about 0.01 % (w/w) and about 1%
  • said biopolymer is in the form of chitosan, added in an amount between about 0.01% (w/w) and about 10% (w/w) by weight, and added in an amount preferably from about 0.01% (w/w) to about 1.5% (w/w) and most preferably about 0.5% (w/w) said chitosan being US pharmacopeia conformant with regard to its functional excipient category and selected from any grades such as Long Chain, Medium Chain & Short Chain, and has a molecular weight in the range between 50 kDa to 5000 kDa,
  • said primary and secondary emulsifiers are selected from a group comprising Cetostearyl alcohol, Cetomacrogol-1000, Cetyl alcohol, Stearyl alcohol, Isopropyl Myristate, Polysorbate-80, Span-80 and the like from about 1% (w/w) to 25% (w/w); said waxy materials is selected from a group comprising White Soft Paraffin, Liquid Paraffin, Hard Paraffin and the like, or any combination thereof, and added in an amount from about 5% (w/w) to 30% (w/w); said co-solvent is selected from a group comprising Propylene Glycol, Hexylene Glycol, PolyEthylene Glycol-400 and the like, or any combination thereof, and added in an amount from about 5% (w/w) to 50% (w/w); said acid is selected from a group comprising HC1, H 2 SO 4 , HNO 3 , Lactic acid and the like, or any combination thereof, and added in an amount from about 0.00
  • Embodiment no. 4 A novel cream as disclosed in the embodiment no. 1 and the embodiment no. 2, further comprising a buffering agent which is selected from a group comprising Orthophosphoric acid, Di Sodium Hydrogen Ortho Phosphate, Sodium Hydrogen Ortho Phosphate and the like, or any combination thereof, and added in an amount from about 0.01% (w/w) to 1.% (w/w).
  • a buffering agent which is selected from a group comprising Orthophosphoric acid, Di Sodium Hydrogen Ortho Phosphate, Sodium Hydrogen Ortho Phosphate and the like, or any combination thereof, and added in an amount from about 0.01% (w/w) to 1.% (w/w).
  • Embodiment no. 5 A novel cream as disclosed in the embodiment no. 1, 2, or 3, further comprising an antioxidant which is selected from a group comprising Butylated Hydroxy Anisole, Butylated Hydroxy Toluene and the like, either singly or any combination thereof, to form a proportion from about 0.001% (w/w) to 5% (w/w).
  • an antioxidant which is selected from a group comprising Butylated Hydroxy Anisole, Butylated Hydroxy Toluene and the like, either singly or any combination thereof, to form a proportion from about 0.001% (w/w) to 5% (w/w).
  • Embodiment no. 6 A novel cream as disclosed in the embodiments 1 to 4, further comprising a chelating agent which is selected from a group comprising Disodium EDTA and the like, or any combination thereof, and added in an amount from about 0.05%> (w/w) to 1%> (w/w).
  • a chelating agent which is selected from a group comprising Disodium EDTA and the like, or any combination thereof, and added in an amount from about 0.05%> (w/w) to 1%> (w/w).
  • Embodiment no. 7 A novel cream as disclosed in the embodiments 1 to 6, further comprising a humectant which is selected from a group comprising Glycerin, Propylene Glycol, Sorbitol, and the like, or any combination thereof, and added in an amount from about 5% (w/w) to 20% (w/w).
  • a humectant which is selected from a group comprising Glycerin, Propylene Glycol, Sorbitol, and the like, or any combination thereof, and added in an amount from about 5% (w/w) to 20% (w/w).
  • Embodiment no. 8 A process of making a cream is disclosed, said process comprising the steps of providing Mometasone Furoate, and chitosan as a biopolymer in a cream base comprising at least one of each of a primary and a secondary emulsifier, a waxy material, a co-solvent, a preservative, a chelating agent, a buffering agent, a penetration enhancer, an acid, and water, preferably purified water, and mixing all the ingredients together to form a homogeneous cream.
  • Embodiment no. 9 A process of making a cream as disclosed in the embodiment no. 8, wherein the ingredients further comprise any of a group comprising an antioxidant, a humectant, or any combination thereof.
  • Embodiment no. 10 A process of making a cream as disclosed in embodiments 7 or 8, wherein said Mometasone Furoate is provided in an amount between about 0.001% (w/w) to about 5% (w/w) by weight, preferably from about 0.01% (w/w) to about 1%) (w/w) by weight and most preferably about 0.1 % (w/w) by weight, and,
  • said chitosan is being provided in an amount between about 0.01% (w/w) to about 10%) (w/w) by weight, preferably from about 0.01%> (w/w) to about 1.5% (w/w) by weight and most preferably about 0.5% (w/w) by weight (Molecular Weight - 50 kDa to 5000 kDa).
  • said primary and secondary emulsifier is selected from a group comprising Cetostearyl alcohol, Cetomacrogol-1000, Cetyl alcohol, Stearyl alcohol, Isopropyl Myristate, Polysorbate-80, Span-80 and the like from about 1% (w/w) to 25% (w/w), said waxy material is selected from a group comprising White Soft Paraffin, Liquid Paraffin, Hard Paraffin and the like from about 5% (w/w) to 30% (w/w),
  • said co-solvent is selected from a group comprising Propylene Glycol, Hexylene Glycol, PolyEthylene Glycol-400 and the like from about 5% (w/w) to 50% (w/w),
  • said acid is selected from a group comprising such as HC1, H 2 SO 4 , HNO 3 , Lactic acid and the like from about 0.005% (w/w) to 1% (w/w)
  • said penetration enhancers are selected from a group comprising Iso Propyl Myristate, Dimethyl Sulphoxide, 2-Pyrrolidone and the like from about 1% (w/w) to 20% (w/w)
  • said preservatives are selected from a group comprising Methylparaben, Propylparaben, Chlorocresol, Potassium sorbate, Benzoic acid,
  • Phenoxyethanol, Benzyl alcohol and the like from about 0.02% (w/w) to 0.5% (w/w),
  • said chelating agents are selected from a group comprising Disodium
  • EDTA and the like from about 0.05% (w/w) to 1% (w/w),
  • said buffering agents are selected from a group comprising
  • Hydrogen Ortho Phosphate and the like from about 0.01% (w/w) to 1.%
  • said water is added in the amount in the range of 20% (w/w) to 75% (w/w), preferably 35% (w/w) to 60% (w/w), preferably purified water,
  • said antioxidant is selected from a group comprising Butylated Hydroxy Anisole, Butylated Hydroxy Toluene and the like, either singly or any combination thereof, to form a proportion from about 0.001% (w/w) to 5%
  • said humectants are selected from a group comprising Glycerin, Propylene Glycol, Sorbitol, and the like from about 5% (w/w) to 20% (w/w), and combining/mixing the above ingredients to make a pharmaceutically acceptable cream.
  • Embodiment no. 11 A novel cream as disclosed in any of the foregoing embodiments, wherein chitosan has a molecular weight range of 50 kDa to 5000 kDa.
  • API-stability experiments were carried out using the product of the present invention and products currently commercially available. Tests were carried out to observe (or measure as appropriate) the physical appearance of the product, the pH value and assay of the API over a period of time. Tests were also carried out to assess the stability by subjecting the product to stress studies such as autoclave test and oxidative degradation test. Further, in vitro antimicrobial zone of inhibition studies and preclinical studies such as blood clotting studies, in vitro diffusion study& skin blanching study were also carried out over a period of time. Each gram of product of the present invention used for the tests contained Mometasone Furoate (0.1% w/w) in the finished product. The product used for the Stability Studies tests contained approximately 5% extra API (overages).
  • the product of the present invention used for studies contained Mometasone Furoate (0.1% w/w). It was packaged in an aluminum collapsible tube and each gram of the product contained 1 mg of Mometasone Furoate (in conformance with USP).
  • PRODUCT NAME MOMETASONE FUROATE CREAM
  • PACK Aluminum collapsible tube Composition: for each g: Mometasone Furoate 0.1% (w/w)
  • Measured parameter pH Limit of measured parameter: 4.0 - 5.5
  • Measured parameter pH Limit of measured parameter: 4.0 -
  • Measured parameter pH Limit of measured parameter: 4.0 - 5.5
  • product of the present invention is quite stable at ambient conditions and also at elevated temperature & humid conditions of storage. This is a major advantage over the currently available Mometasone Furoate Cream.
  • the stability of the product is further ascertained by the shelf-life prediction of the formulation using Arrhenius plot of degradation employing Nova-LIMS software.
  • the enhanced stability of the present invention is achieved by the addition of biopolymer to the formulation.
  • the cream is applied after thorough cleansing and drying the affected area. Sufficient cream should be applied to cover the affected skin and surrounding area. The cream should be applied two - four times a day depending upon the skin conditions for the full treatment period, even though symptoms may have improved.
  • Blood clotting time was observed in both groups of animals, untreated control group and the test group of animals treated with the product of the present invention. Statistically significant decrease in the blood clotting time in treated group animals was observed when compared with that of the control group animals. The mean percent reduction of 19.35% was observed for the blood clotting time using the product of the present invention.
  • test product and reference product were evaluated by performing the release studies by diffusion using keshary chein apparatus. Formulation of test and reference product was released about 38.6% and 28.5% of the label claim at the end of 9 hours respectively.
  • the Skin inflammatory Study was concluded statistically that the Croton oil application in to ear of rats has produced 70% edema in control group.
  • the present invention formulations of Mometasone Furoate Cream and market Cream have reduced the edema produced by croton oil.
  • the highest reduction in edema is by Mometasone Furoate Cream (invention) was found when compared with marketed product.
  • the primary skin irritation is the production of reversible damage in the skin. Topical exposure of chemicals, drugs etc., can lead to the adverse skin effects. According to the severity and reversibility of effects, the products can be distinguished into irritant or corrosive. So the experimental study was performed to assess the possible hazard likely to arise from exposure of topical formulation to the human skin. Thus, primary skin irritation study was carried out for the newly formulated dermal cream - Mometasone Furoate Cream (invention) to determine its irritant response to the skin after single exposure. From the experimental study it was concluded that the formulation of Mometasone Furoate Cream (invention) scored the primary skin irritation index of 0. Hence, the Mometasone Furoate Cream (invention) was non-irritant and dermal-friendly.
  • VAS score data shows that mean visual analogue scale score for present invention of invention 2.4 whereas commercially available cream is 1.3 at visit 3, it clearly indicates that severity of wound is lesser in present invention.
  • GMI Global score index
  • PGES Physician global evaluation score
  • the therapeutic efficacy of topically applied cream of the present invention is due to the pronounced anti-inflammatory activity of the Mometasone Furoate against the inflammation, the unique ability of actives to penetrate intact skin and wound healing & soothing properties of Chitosan.
  • the cream of the present invention incorporates a skin- friendly biopolymer in the form of Chitosan provides enhanced therapeutic outcomes. This is evident from the reduced blood clotting time, increased epithelial effect, and faster relief from infection and inflammation.
  • the cream of the present invention incorporates a biopolymer without compromising the stability of the cream matrix and without adversely affecting the functioning of known active pharmaceutical ingredients. This has been achieved through a careful selection of functional excipients to bypass undesirable aspects of physio-chemical compatibility/stability and bio- release.
  • the cream of the present invention provides an integrated unit-dose or a single-dose therapy hitherto unavailable in prescription dermaceutical formulations.
  • the novel cream of the present invention is adequately stable/efficacious at ambient conditions and does not need special temperature control during transportation/storage - hence will go a long way in achieving these social objectives with longer shelf-life.
  • the therapeutic efficacy of topically applied innovative anti-inflammatory cream with Chitosan is due to the pronounced activity of the active Mometasone Furoate - corticosteroid against skin inflammations - dermatitis & allergic conditions, the unique ability of actives to penetrate intact skin and skin regeneration & rejuvenation, wound healing and soothing properties of Chitosan.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une composition pour le traitement d'une inflammation cutanée (dermatite), la régénération et le rajeunissement de la peau et la cicatrisation des plaies contenant un composant de chitosane utilisé pour le traitement de régénération et de rajeunissement de la peau et de cicatrisation des plaies, du furoate de mométasone utilisé dans le traitement d'inflammations cutanées, une base de crème contenant l'un quelconque des ingrédients choisis dans un groupe comprenant des émulsifiants primaires et secondaires, des substances cireuses, des cosolvants, des acides, des conservateurs, des agents tampons, des antioxydants, des chélateurs, et des humidifiants et de l'eau purifiée. L'invention présente l'avantage de réduire le temps de coagulation du sang, d'augmenter un effet épithélial et de soulager plus rapidement l'infection et l'inflammation. L'invention concerne également une thérapie à dose unitaire intégrée ou à dose unique jusqu'à présent indisponible dans des formulations dermaceutiques de prescription. En outre, l'invention est adéquatement stable/efficace en conditions ambiantes et ne nécessite pas de contrôle particulier de la température pendant le transport/stockage.
PCT/IB2016/053261 2015-06-10 2016-06-03 Crème médicale préparée en utilisant du furoate de mométasone et en incorporant un biopolymère et procédé pour la préparer Ceased WO2016199002A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/368,559 US20170119788A1 (en) 2015-06-10 2016-12-02 Methods and compositions for dermatological use comprising fluticasone and mometasone and biopolymers

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2897CH2015 2015-06-10
IN2897/CHE/2015 2015-06-10

Related Child Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2016/053258 Continuation-In-Part WO2016198999A1 (fr) 2015-06-10 2016-06-03 Crème médicinale préparée en utilisant du propionate de fluticasone et en incorporant un biopolymère et procédé pour la préparer

Publications (1)

Publication Number Publication Date
WO2016199002A1 true WO2016199002A1 (fr) 2016-12-15

Family

ID=56369062

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2016/053261 Ceased WO2016199002A1 (fr) 2015-06-10 2016-06-03 Crème médicale préparée en utilisant du furoate de mométasone et en incorporant un biopolymère et procédé pour la préparer

Country Status (1)

Country Link
WO (1) WO2016199002A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100240621A1 (en) * 2007-09-10 2010-09-23 Glenmark Pharmaceuticals Ltd. Topical pharmaceutical composition for the combination of fusidic acid and a corticosteroid
WO2010119384A2 (fr) * 2009-04-13 2010-10-21 Sulur Subramaniam Vanangamudi Crème médicale à base de furorate de mométasone et de chitosane et son procédé de préparation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100240621A1 (en) * 2007-09-10 2010-09-23 Glenmark Pharmaceuticals Ltd. Topical pharmaceutical composition for the combination of fusidic acid and a corticosteroid
WO2010119384A2 (fr) * 2009-04-13 2010-10-21 Sulur Subramaniam Vanangamudi Crème médicale à base de furorate de mométasone et de chitosane et son procédé de préparation

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHEN.C. ET AL.: "preparation and characterization of biodegradable Poly (L-lactide)/Chitosan blend", EUROPEAN POLYMER JOURNAL, vol. 41, no. 5, 2005, pages 958 - 66
DUNIA.M. ET AL.: "physical interactions in macro porous scaffolds based on poly (Caprolactone)/ Chitosan semi-interpenetrating polymer network", POLYMER, vol. 50, 2009, pages 2058 - 64
SENYIGIT T ET AL: "Different approaches for improving skin accumulation of topical corticosteroids", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER BV, NL, vol. 380, no. 1-2, 1 October 2009 (2009-10-01), pages 155 - 160, XP026715213, ISSN: 0378-5173, [retrieved on 20090725], DOI: 10.1016/J.IJPHARM.2009.07.018 *
X.W.TENG ET AL., INTERNATIONAL JOURNAL OF PHARMACEUTICALS, vol. 259, 2003, pages 129 - 141
YUSHENG. Q. ET AL.: "Enhanced mechanical performance of Poly(propylene carbonate) via hydrogen bonding interaction with o-lauryl Chitosan", CARBONATE POLYMER, vol. 84, 2011, pages 329 - 34, XP028151904, DOI: doi:10.1016/j.carbpol.2010.11.045

Similar Documents

Publication Publication Date Title
US8546362B2 (en) Medicinal cream made using neomycin sulphate, betamethasone valerate, and chitosan, and a process to make the same
WO2010109434A2 (fr) Crème médicinale antibactérienne, antifongique et contenant des stéroïdes, et procédé pour la préparer
US20120022019A1 (en) Medicinal Steroids Cream And A Process To Make It
US20120136071A1 (en) Medicinal Cream For Diaper Rash And A Process To Make It
US20120028943A1 (en) Medicinal Cream Made Using Fluticasone Propionate And Chitosan And A Process To Make The Same
US20120035144A1 (en) Medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, a corticosteroid, and an antifungal agent, and a process to make it.
US20120270835A1 (en) Medicinal Cream Made Using Hydrocortisone Acetate and A Process To Make The Same
WO2010109424A1 (fr) Crème médicinale antibactérienne renfermant des stéroïdes et du chitosane, et son procédé de production
WO2016198997A1 (fr) Crème médicale préparée en utilisant du valérate de bêtaméthasone et en incorporant un biopolymère et procédé pour la préparer
US20120040927A1 (en) Medicinal antifungal and steroid cream incorporating a biopolymer and a process to make it.
WO2016198998A1 (fr) Crème médicale préparée en utilisant du propionate de clobêtasol et en incorporant un biopolymère et procédé pour la préparer
US20120040944A1 (en) medicinal cream made using mometasone furoate and chitosan and a process to make the same
WO2016199002A1 (fr) Crème médicale préparée en utilisant du furoate de mométasone et en incorporant un biopolymère et procédé pour la préparer
US20170119788A1 (en) Methods and compositions for dermatological use comprising fluticasone and mometasone and biopolymers
WO2011101826A1 (fr) Crème médicinale contenant de l'acide fusidique fabriquée à l'aide de fusidate de sodium et incorporant un biopolymère, de la terbinafine et de la dexaméthasone et son procédé de fabrication
US20170119792A1 (en) Methods and compositions for dermatological use comprising clobetasol and halobetasol and biopolymers
US20170119791A1 (en) Methods and compositions for dermatological use comprsing betamethasone and biopolymers
WO2016199001A1 (fr) Crème médicinale préparée en utilisant de l'acétate d'hydrocortisone et en incorporant un biopolymère et procédé pour la préparer
WO2016198996A1 (fr) Crème médicale préparée en utilisant du dipropionate de bêtaméthasone et en incorporant un biopolymère et procédé pour la préparer
WO2010122493A1 (fr) Crème médicinale à base d'acide fusidique préparée avec du fusidate de sodium et incorporant un biopolymère, un corticostéroïde et un agent antifongique, et son procédé de fabrication
US20120115828A1 (en) Medicinal cream containing miconazole nitrate, hydrocortisone acetate, and a biopolymer, and a process to make it
WO2016199000A1 (fr) Crème médicale préparée en utilisant du propionate d'halobêtasol et en incorporant un biopolymère et procédé pour la préparer
WO2010122476A1 (fr) Crème médicinale à base d'acide fusidique préparée avec du fusidate de sodium et incorporant un biopolymère, du miconazole et du mométasone, et son procédé de fabrication
WO2016198999A1 (fr) Crème médicinale préparée en utilisant du propionate de fluticasone et en incorporant un biopolymère et procédé pour la préparer
WO2010122494A1 (fr) Crème médicinale à base d'acide fusidique préparée avec du fusidate de sodium et incorporant un biopolymère et du mométasone, et son procédé de fabrication

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16736240

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16736240

Country of ref document: EP

Kind code of ref document: A1